Page 2 - Nasdaq Stsa News Today

Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash...

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 159,400 shares, a decrease of 40.4% from the March 15th total of 267,500 shares. Based on an average trading volume of 152,700 shares, the […]

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating)‘s stock had its “neutral” rating reaffirmed by stock analysts at Mizuho in a research note issued on Thursday, Benzinga reports. They presently have a $2.00 price target on the financial services provider’s stock. Mizuho’s price target indicates a potential upside of 180.62% from the stock’s previous close. Satsuma Pharmaceuticals […]

Thursday, June 16th @ 10:30 a.m. ET...

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $4.17. Satsuma Pharmaceuticals shares last traded at $3.86, with a volume of 57,425 shares changing hands. STSA has been the topic of several […]

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) issued its quarterly earnings data on Tuesday. The financial services provider reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49), MarketWatch Earnings reports. Shares of NASDAQ:STSA traded down $0.01 during trading on Thursday, reaching $3.78. The stock had a trading volume of 34,273 shares, compared to […]